Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
555 questions in 79 reviews · Musculoskeletal
current versionsNo studies 555 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Custom foot orthoses vs prefabricated foot orthoses Quality of life · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Custom foot orthoses vs prefabricated foot orthoses Treatment success · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Customised foot orthoses vs shoes Function or disability · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Custom foot orthoses vs prefabricated foot orthoses Adverse events · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Custom foot orthoses vs prefabricated foot orthoses Serious adverse events · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Custom foot orthoses vs shoes Adverse events · children with juvenile idiopathic arthritis (JIA) and flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Custom foot orthoses vs shoes Serious adverse events · children with juvenile idiopathic arthritis (JIA) and flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Customised foot orthoses vs shoes Quality of life · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Adverse events · children with juvenile idiopathic arthritis and flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Serious adverse events · children with juvenile idiopathic arthritis and flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Customised foot orthoses vs shoes Treatment success · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Custom foot orthoses vs prefabricated foot orthoses Adverse effects · children with juvenile idiopathic arthritis and flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Custom foot orthoses vs prefabricated foot orthoses Serious adverse events · children with juvenile idiopathic arthritis and flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Pain · children with symptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Treatment success · children with symptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Withdrawal due to adverse events · children with symptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Adverse effects · children with symptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Serious adverse events · children with symptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Customised foot orthoses vs shoes Adverse events · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Customised foot orthoses vs shoes Serious adverse events · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Prefabricated foot orthoses vs shoes Function or disability · children with asymptomatic flat feet Foot orthoses for treating paediatric flat feet (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous myeloablative selective HSCT vs cyclophosphamide Pulmonary arterial hypertension · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide Event‐free survival · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide Functional ability – HAQ‐DI Scale 0–3 with 0 representing no/mild impairment and 3 representing very severe impairment. The study incorporated a ≥ 0.4 threshold · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide Pulmonary arterial hypertension · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Autologous non‐myeloablative selective HSCT vs cyclophosphamide Pulmonary arterial hypertension · people with systemic sclerosis Stem cell transplantation for systemic sclerosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Adjunctive therapies in addition to land‐based exercise therapy vs land‐based exercise therapy Withdrawals due to adverse events · osteoarthritis of the hip or knee Adjunctive therapies in addition to land‐based exercise therapy for osteoarthritis of the hip or knee (2022) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose colchicine vs placebo Pain ‐ not reported · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose colchicine vs placebo Function of target joint ‐ not measured · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs low‐dose colchicine Pain ‐ not reported · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs low‐dose colchicine Reduction of inflammation ‐ not measured · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose vs low‐dose colchicine Function of target joint ‐ not measured · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose colchicine vs NSAIDs Reduction of inflammation ‐ not measured · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose colchicine vs NSAIDs Function of target joint ‐ not measured · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose colchicine vs NSAIDs Serious adverse events · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose colchicine vs NSAIDs Withdrawals due to adverse events · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose colchicine vs placebo Reduction of inflammation ‐ not measured · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Low‐dose colchicine vs placebo Function of target joint ‐ not measured · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
High‐dose colchicine vs placebo Pain ‐ not reported · people with acute gout Colchicine for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound‐guided injection vs non‐image‐guided injection Serious adverse events Not reported · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Ultrasound‐guided injection vs non‐image‐guided injection Number of withdrawals due to adverse events · Patients with shoulder pain Image‐guided glucocorticoid injection versus injection without image guidance for shoulder pain (2021) · Cochrane | no estimate extracted | NR | No studies |
Monthly pegloticase vs placebo Quality of life ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Monthly pegloticase vs placebo Serum urate normalisation ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Monthly pegloticase vs placebo Function ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Joint pain reduction ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Quality of life ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Serum urate normalisation ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Pegloticase every two weeks (biweekly) vs placebo Function ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
Monthly pegloticase vs placebo Joint pain reduction ‐ not reported · participants with tophi in gout Interventions for tophi in gout (2021) · Cochrane | no estimate extracted | NR | No studies |
NSAIDs vs glucocorticoids Health‐related quality of life (HRQoL)Not reported · acute gout Non‐steroidal anti‐inflammatory drugs for acute gout (2021) · Cochrane | no estimate extracted | NR | No studies |